# Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

> **NCT05064085** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 13 (actual)

## Conditions studied

- Hormone Receptor-positive Breast Cancer

## Interventions

- **DRUG:** Cemiplimab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT05064085
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-12
- **Primary completion:** 2024-09-09
- **Final completion:** 2025-03-13
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05064085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05064085, "Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05064085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*